Texas Sues Meta Platforms Over Facebook’s Recognition Practices

-Dow Jones

byBenzinga Newsdesk

February 14, 2022

1 minute read

-Dow Jones

Morgan Stanley Maintains Overweight on Apollo Global Management, Raises Price Target to $79

By Benzinga Newsdesk

Today, 6:48 AM

Morgan Stanley analyst Michael Cyprys maintains Apollo Global Management (NYSE:APO) with a Overweight and raises the price target from $73 to $79.

APO

Legal
News

Cel-Sci Corporation Files For U.S. Patent Titled ‘NOVEL PEPTIDES FOR VACCINATION AND TREATMENT OF 2019-nCoV INFECTIONS’

By Benzinga Newsdesk

Today, 6:48 AM

https://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.html&r=6592&p=132&f=G&l=50&d=PG01&S1=20210902.PD.&OS=PD/20210902&RS=PD/20210902

CVM

Heron Therapeutics Reports Filing Of Supplemental New Drug Application For Expansion Of ZYNRELEF Indication Statement

By Benzinga Newsdesk

Today, 6:48 AM

- FDA agreed to the immediate filing of supplemental NDA to significantly expand the ZYNRELEF indication statement based on previously submitted data with no new clinical studies - - FDA also agreed on the required

HRTX

FDA
News

Apyx Medical Corporation Announces Results Of The U.S. Ide Clinical Study Evaluating The Use Of Renuvion To Improve The Appearance Of Lax Skin In The Neck And Submental Region; Says Primary Effectiveness Endpoint Of Study Was Met

By Benzinga Newsdesk

Today, 6:48 AM

Apyx Medical Corporation (NASDAQ:APYX) (the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that the results of

APYX

Texas Sues Meta Platforms Over Facebook’s Recognition Practices

Related Posts

Morgan Stanley Maintains Overweight on Apollo Global Management, Raises Price Target to $79

Cel-Sci Corporation Files For U.S. Patent Titled ‘NOVEL PEPTIDES FOR VACCINATION AND TREATMENT OF 2019-nCoV INFECTIONS’

Heron Therapeutics Reports Filing Of Supplemental New Drug Application For Expansion Of ZYNRELEF Indication Statement

Apyx Medical Corporation Announces Results Of The U.S. Ide Clinical Study Evaluating The Use Of Renuvion To Improve The Appearance Of Lax Skin In The Neck And Submental Region; Says Primary Effectiveness Endpoint Of Study Was Met